BiotechTube
SYNDIVIA

SYNDIVIA

Paris, France· Est.
syndivia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Syndivia is a private, preclinical-stage biotech developing next-generation antibody-drug conjugates (ADCs) through its proprietary GeminiMab platform. The platform's key differentiator is its ability to perform site-specific conjugation at the native antibody hinge region without requiring enzyme engineering or sequence modification, enabling optimal DARs (1, 2, 4) and preserving antibody integrity. This approach is designed to create ADCs with enhanced therapeutic windows through improved tumor penetration and safety profiles. The company is building a proprietary pipeline of ADC candidates while actively protecting its technology through an extensive patent strategy.

Oncology

Technology Platform

GeminiMab platform for site-specific hinge-region conjugation of native antibodies, enabling homogeneous ADCs with controlled DAR (1,2,4) without antibody engineering.

Opportunities

The global ADC market is expanding rapidly, creating demand for improved technologies.
Syndivia's unique DAR1 capability and simple, native antibody conjugation process could enable safer, more efficacious ADCs, particularly with highly potent payloads.
The platform may also be applicable beyond cytotoxics to other conjugated modalities.

Risk Factors

The platform is unproven in clinical trials, facing significant technical and translational risk.
The company operates in an intensely competitive ADC technology landscape against well-capitalized players.
As a private, preclinical firm, it carries high financial risk and dependence on future funding.

Competitive Landscape

Syndivia competes with numerous established ADC technology companies (e.g., ImmunoGen, Seagen/ Pfizer, Mersana) and large pharma internal platforms. Its differentiation lies in hinge-region site-specificity without antibody modification, a claim distinct from enzymatic (e.g., sortase, transglutaminase) or engineered cysteine/unnatural amino acid approaches.

More companies in Antibody-Drug Conjugates →More companies in France →